Back to discover
Disease
Adrenocortical Carcinoma
Late-stage therapeutic developmentEmerging research
1
Publications
19
Clinical trials
2020
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2020-08-27Annals of oncology : official journal of the European Society for Medical Oncology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy
- Q4 2027Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- Q1 2028A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-07-10
Upcoming trial readoutImportant
Results expected Q1 20282026-05-22
Clinical MilestonesViewHide
Results expected
- 2026-07-10Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaResults expected Q4 2027
- 2026-05-22A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)Results expected Q1 2028
- 2026-01-23A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based ChemotherapyResults expected Q1 2027
Activity timeline3
- 2026-07-10ClinicalPhase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaResults expected Q4 2027
- 2026-05-22ClinicalA Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)Results expected Q1 2028
- 2026-01-23ClinicalA Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based ChemotherapyResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
2
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes4
- Adrenal Cortex Neoplasms1
- Adrenal Gland Neoplasms1
- Adrenocortical Carcinoma1
- Pheochromocytoma1
Leading journals1
- Annals of oncology : official journal of the European Society for Medical Oncology1
Leading researchers8
- Assie G1
- Baudin E1
- Berruti A1
- de Krijger R1
- de la Fouchardiere C1
- Eisenhofer G1
- Fassnacht M1
- Haak HR1
Affiliations (unnormalised)6
- Centre Léon Bérard1
- Department of Clinical and Biological Sciences1
- Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine1
- Maastricht University Medical Centre1
- Reference Centre for Rare Adrenal Diseases1
- San Luigi Hospital - Orbassano1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.